You are currently viewing Lobe Sciences Announces Filing of PCT Application

Lobe Sciences Announces Filing of PCT Application

PCT filing further strengthens the Company’s intellectual property portfolio

Vancouver, British Columbia–(Newsfile Corp. – April 29, 2021) –  Lobe Sciences Ltd. (“Lobe” or the “Company“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the filing of a key Patent Cooperation Treaty (“PCT”) application entitled Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder.

Philip Young, CEO and Director of Lobe stated, “We are committed to pursuing patent protection for our inventions as we continue with our development initiatives. It is important that our intellectual property is safeguarded as we continue on our path to drug and device development, and prepare for our clinical trials.”

The Company’s PCT filing includes details that were previously submitted in three separate US provisional patent applications filed with the U.S. Patent and Trademark Office (“USPTO”). The PCT is an international patent law treaty which provides a unified procedures for filing patent application to protection inventions in each of its member states. By filing one international patent application under the PCT, the Company can simultaneously seek protection for an invention in 153 countries.

The PCT application relates to methods for treating or alleviating symptoms of mild traumatic brain injury (“mTBI”), post-traumatic stress disorder (“PTSD”) and mTBI with PTSD via administration of a psychedelic agent in combination with N-acetylcysteine (“NAC”). In addition, the application relates to the Company’s nasal mist transducer as well as methods and kits for alleviating symptoms of mTBI, PTSD and mTBI with PTSD using a psychedelic agent and NAC in combination with memory-odor imprint pairing.

About Lobe Sciences Ltd.

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.